The Jerusalem PostOdds rise of Trump-Kim meeting on APEC sidelines, analysts sayInquirer6 hurt after truck crashes into warehouse in Benguet townPunchObasa celebrates son’s LG chairman of the year awardDaily MaverickSomaliland briefly detains Americans accused of threatening national securityInquirer EntertainmentBINI, SB19 celebrate historic Grammy nominationsZDF heuteAktuelle Pressemitteilungen des ZDFCNN بالعربيةالنصر ينشر صورة لرونالدو بجانب علم السعودية.. وهكذا علّق عليهاVarietyIndian Actress and Director Nandita Das, Syrian Star Taim Hassan to Be Honored by Doha Film FestivalRTL BoulevardIsraël uploadde miljoenen foto's van Palestijnen naar Amazon-cloud voor gezichtsherkenningIl Fatto QuotidianoPapa Leone: “Dopo le midterm mi aspetto meno guerre. Lettera di dimissioni preventive in caso di problemi di salute? Non ne vedo la necessità”Straits Times SportFernando Alonso to enter Dakar Rally with Sebastien Loeb and Aston Martin teamБи-би-сиКрымский мост получил повреждения после второго за сутки украинского удара
The Daily Newsstand · Free, Always
Tuesday, November 17, 2026

IMDX expects to submit FDA response before Jan. 21, 2027 deadline as it targets $800M U.S. kitted transplant testing market

Translate

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q3 2026

Management View

  • “Today, I will focus on 2 main topics: start of U.S. revenue from GraftAssure and what we believe will be the final steps related to our FDA submission.” (President, CEO & Director Joshua Riggs)

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.